HLA-E单链三聚体保护基因编辑异体CAR-T免受NK细胞攻击
该研究针对异体CAR-T细胞因MHC-I敲除触发NK细胞missing-self反应的问题,构建表达HLA-E-ESP-1C单链三聚体的通用异体CAR-T(UCART)细胞。体外及体内实验显示其可抵抗NKG2A+细胞活化、对NKG2C+细胞激活微弱,联合CD54/CD58敲除后对异质性NKG2A+/C+NK细胞群抵抗最佳,在人源化小鼠模型中UCART19实现严格肿瘤控制。
要点
- HLA-E呈递VMAPRTLIL信号肽可赋予UCART抵抗NKG2A+细胞的能力。
- 联合CD54与CD58敲除可优化对异质性NKG2A+/C+NK细胞群的抵抗。
- 人源化小鼠模型中UCART19展现严格肿瘤控制,支持临床转化。
核心结论
- 表达HLA-E-ESP-1C单链三聚体并联合CD54/CD58敲除的UCART细胞可逃避NK细胞missing-self反应,体内外表现与自体CAR-T相似。
研究设计与样本
- 临床前研究,涉及体外实验与人源化小鼠模型,具体样本量原文未报告。
主要发现
- HLA-E呈递VMAPRTLIL(HLA-ESP-1C)赋予对NKG2A+细胞群的抵抗,对NKG2C+细胞群激活可忽略。
- CD54和CD58敲除联合HLA-ESP-1C表达对异质性NKG2A+/C+NK细胞群产生最佳抵抗。
- 人源化小鼠模型 reconstituted with allogeneic NK cells 中,UCART19细胞促进严格肿瘤控制。
临床怎么用
- 提示异体CAR-T设计可引入HLA-E-ESP-1C并联合CD54/CD58敲除以规避NK细胞排斥,推动临床转化。
局限性
- 证据主要来自体外及人源化小鼠模型,临床安全性与有效性尚待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic chimeric antigen receptor (CAR) T-cell therapies hold promise for certain malignant disorders, as they allow for scalability, on-demand availability, and enhanced product quality. Currently, allogeneic CAR T-cell approaches focus on deleting the αβ T-cell receptor complex and major histocompatibility complex (MHC)-I/II from CAR T cells to prevent graft-versus-host disease and rejection of allogeneic cells by the recipient's immune system. However, genetic ablation of MHC-I leads to natural killer (NK) cell activation in recipients because of the missing-self response. Here, we demonstrate the successful generation of universal allogeneic CAR T (UCART) cells that evade the NK cell's missing-self response and display similar performance to autologous CAR T cells both in vitro and in vivo. An HLA single-chain trimer platform enabled the demonstration that HLA-E presentation of a defined signal peptide sequence, VMAPRTLIL (designated as HLA-ESP-1C), confers resistance to NKG2A+ cell populations with negligible activation of NKG2C+ cell populations. Examination of additional receptor-ligand interactions that may impact NK cell activation confirmed that CD54 and CD58 ablation on UCART cells, in combination with HLA-ESP-1C expression, led to optimal resistance to heterogeneous NKG2A+/C+ NK cell populations. Finally, in a humanized mouse model reconstituted with allogeneic NK cells, we demonstrated that UCART19 cells promote stringent tumor control. Our work suggests an updated approach for allogeneic CAR T-cell therapy in clinical applications.
引用
- Apodaca KM, Xu C, Stanton KL, et al. HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack. Blood Adv. 2026. PMID: 41945756. doi:10.1182/bloodadvances.2025016927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。